These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22644710)

  • 1. Comment on Hsiao et al.: Correlation of early-phase ¹⁸F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.
    Ballinger JR
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1512; author reply 1513. PubMed ID: 22644710
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.
    Hsiao IT; Huang CC; Hsieh CJ; Hsu WC; Wey SP; Yen TC; Kung MP; Lin KJ
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):613-20. PubMed ID: 22270508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-phase
    Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
    J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
    Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
    J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves.
    Broski SM; Spinner RJ; Howe BM; Dispenzieri A; Johnson GB
    Clin Nucl Med; 2016 Feb; 41(2):e115-7. PubMed ID: 26284768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Florbetapir F 18 for brain imaging of β-amyloid plaques.
    Romano M; Buratti E
    Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers.
    Burgos N; Cardoso MJ; Thielemans K; Modat M; Dickson J; Schott JM; Atkinson D; Arridge SR; Hutton BF; Ourselin S
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1447-58. PubMed ID: 26105119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ottoy J; Verhaeghe J; Niemantsverdriet E; De Roeck E; Wyffels L; Ceyssens S; Van Broeckhoven C; Engelborghs S; Stroobants S; Staelens S
    Alzheimers Dement; 2019 Sep; 15(9):1172-1182. PubMed ID: 31405824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score.
    Zukotynski K; Gaudet V; Kuo PH; Adamo S; Goubran M; Scott CJM; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce R; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE
    Clin Nucl Med; 2020 Jun; 45(6):427-433. PubMed ID: 32366785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved preparation of [
    Zhang L; Zhang A; Yao X; Zhang Y; Liu F; Hong H; Zha Z; Liu Y; Wu Z; Qiao J; Zhu L; Kung HF
    J Labelled Comp Radiopharm; 2020 Mar; 63(3):108-118. PubMed ID: 31697847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Added Value of Dynamic 18F-Florbetapir PET in the Assessment of Dementia With Lewy Bodies.
    López-Mora DA; Camacho V; Lleó A; Fernández A; Carrió I
    Clin Nucl Med; 2018 Mar; 43(3):e85-e86. PubMed ID: 29261640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
    Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
    Landau SM; Mintun MA; Joshi AD; Koeppe RA; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
    Ann Neurol; 2012 Oct; 72(4):578-86. PubMed ID: 23109153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.